期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 125, 期 2, 页码 S95-S102出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2009.10.047
关键词
Asthma; respiratory syncytial virus; rhinovirus; allergen; prevention; exacerbation; inception; treatment
资金
- National Institutes of Health [1P01HL70831-01, HL56396, AI50500]
- Novartis
- Centocor
- GlaxoSmithKline
- MedImmune
- Ception
- National Institutes of Health-National Institute of Allergy and Infectious Diseases
- National Heart, Lung, and Blood Institute
Asthma is a complex disorder that displays heterogeneity and variability in its clinical expression both acutely and chronically. This heterogeneity is influenced by multiple factors including age, sex, socioeconomic status, race and/or ethnicity, and gene by environment interactions. Presently, no precise physiologic, immunologic, or histologic characteristics can be used to definitively make a diagnosis of asthma, and therefore the diagnosis is often made on a clinical basis related to symptom patterns (airways obstruction and hyperresponsiveness) and responses to therapy (partial or complete reversibility) over time. Although current treatment modalities are capable of producing control of symptoms and improvements in pulmonary function in the majority of patients, acute and often severe exacerbations still occur and contribute significantly to both the morbidity and mortality of asthma in all age groups. This review will highlight some of the important clinical features of asthma and emphasize recent advances in both pathophysiology and treatment. (J Allergy Clin Immunol 2010;125:S95-102.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据